Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
217
Recruiting, any sponsor type, condition "endometrial"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting217
- Completed454
217 trials
Showing 1 to 25, recently updated first.
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07198074 · 255 participants (planned) · Start Jan 27, 2026 · Primary completion Jul 1, 2028
Drug: Bevacizumab; Carboplatin and 2 more · For: Advanced Endometrial Carcinoma; Recurrent Endometrial Carcinoma
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 311 sites in all
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07578649 · 600 participants (planned) · Start Nov 5, 2026 · Primary completion Sep 29, 2029
Drug: PF-08634404; Pembrolizumab and 1 more · For: Endometrial Neoplasms; Endometrial Cancer
Sites: Jupiter, Florida; Orlando, Florida; Coon Rapids, Minnesota · 54 sites in all
Whitehawk Therapeutics, Inc.Industry
NCT07444814 · 226 participants (planned) · Start Dec 19, 2025 · Primary completion Sep 2028
Drug: HWK-007 · For: Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic and 4 more
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 17 sites in all
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
Regor Pharmaceuticals Inc.Industry
NCT07524322 · 63 participants (planned) · Start Jul 21, 2026 · Primary completion Apr 2028
Drug: RGT-490 · For: Breast Cancer; Ovarian Cancer; Endometrial Cancer and 6 more
Sites: Los Angeles, California; Boston, Massachusetts; Pittsburgh, Pennsylvania · 7 sites in all
Kestrel Therapeutics, Inc.Academic, hospital or other
NCT07458347 · 545 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 2028
Drug: KST-6051; Gemcitabine/nab-paclitaxel and 6 more · For: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC) and 1 more
Sites: Los Angeles, California; Sarasota, Florida; Tampa, Florida · 9 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
- A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Recruiting
Outpace Bio, Inc.Industry
NCT07664735 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2030
Drug: OPB-201 · For: Endometrial Cancer Recurrent; Endometrial Cancer; Advanced Endometrial Cancer and 4 more
Sites: San Francisco, California; Atlanta, Georgia; Detroit, Michigan · 5 sites in all
University of OklahomaAcademic, hospital or other
NCT07737795 · 66 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: OK-1 & Paclitaxel · For: Endometrial Cancer
Sites: Oklahoma City, Oklahoma
Aaron WolfsonAcademic, hospital or other
NCT05603910 · 18 participants (planned) · Start Apr 15, 2023 · Primary completion Apr 15, 2029
Drug: Lenvatinib; Pembrolizumab · For: Recurrent Endometrial Carcinoma; Unresectable Endometrial Carcinoma
Sites: Miami, Florida
National Cancer Institute (NCI)NIH
NCT05950464 · 65 participants (planned) · Start Dec 18, 2023 · Primary completion Jun 30, 2027
Drug: BET Bromodomain Inhibitor ZEN-3694; Tuvusertib · For: Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma and 6 more
Sites: Augusta, Georgia; Chicago, Illinois; Iowa City, Iowa · 14 sites in all
National Cancer Institute (NCI)NIH
NCT05112601 · 81 participants (planned) · Start Jun 2, 2022 · Primary completion Jul 30, 2032
Drug: Ipilimumab; Nivolumab · For: Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma and 6 more
Sites: Birmingham, Alabama; Athens, Georgia; Augusta, Georgia · 138 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06952504 · 1,123 participants (planned) · Start May 22, 2025 · Primary completion May 24, 2032
Drug: Pembrolizumab; Carboplatin and 4 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Irvine, California · 272 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06172478 · 890 participants (planned) · Start Feb 26, 2024 · Primary completion Nov 19, 2030
Drug: HER3-DXd · For: Advanced Solid Tumor; Melanoma; Head and Neck Cancer and 11 more
Sites: Duarte, California; New Haven, Connecticut; Kissimmee, Florida · 97 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07213609 · 47 participants (planned) · Start Oct 20, 2025 · Primary completion Sep 28, 2028
Drug: GSK5460025 · For: Neoplasms, Colorectal; Neoplasms
Sites: Aurora, Colorado; Detroit, Michigan; Canton, Ohio · 27 sites in all
Yonsei UniversityAcademic, hospital or other
NCT06502743 · 92 participants (planned) · Start Sep 12, 2024 · Primary completion Dec 27, 2027
Drug: Nesuparib; Pembrolizumab · For: Endometrial Cancer; Recurrent Endometrial Carcinoma; Endometrial Carcinoma and 2 more
Sites: Seongnam-si, South Korea; Goyang-si, South Korea; Seoul, South Korea · 8 sites in all
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruiting
Corcept TherapeuticsIndustry
NCT06906341 · 270 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 2027
Drug: Relacorilant 150 mg once daily (QD); Nab-paclitaxel 80 mg/m^2 and 1 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms and 1 more
Sites: Birmingham, Alabama; Palo Alto, California; San Francisco, California · 53 sites in all
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06989112 · 600 participants (planned) · Start Mar 27, 2025 · Primary completion Jan 19, 2029
Drug: Trastuzumab deruxtecan; Rilvegostomig and 4 more · For: Endometrial Cancer
Sites: Tucson, Arizona; Little Rock, Arkansas; Duarte, California · 256 sites in all
Elizabeth Stover, MD, PhDAcademic, hospital or other
NCT06964009 · 30 participants (planned) · Start Sep 22, 2025 · Primary completion Jun 30, 2027
Drug: DT2216; Paclitaxel · For: Ovarian Cancer; Ovarian Carcinoma; Recurrent Ovary Cancer and 4 more
Sites: Boston, Massachusetts · 3 sites in all
Ensem TherapeuticsIndustry
NCT07912593 · 320 participants (planned) · Start Oct 22, 2026 · Primary completion Oct 30, 2028
Drug: ETX-929 dose escalation; ETX-929 dose escalation in combination with cetuximab · For: Metastatic Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Non-squamous, Non-Small Cell Lung Cancer and 3 more
Sites: Fairfax, Virginia
National Cancer Institute (NCI)NIH
NCT01174121 · 332 participants (planned) · Start Aug 26, 2010 · Primary completion Dec 27, 2028
Drug: Pembrolizumab (Keytruda); Fludarabine and 3 more · For: Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer and 2 more
Sites: Bethesda, Maryland
Pliant Therapeutics, Inc.Industry
NCT06270706 · 124 participants (planned) · Start Aug 30, 2023 · Primary completion Jun 2030
Drug: PLN-101095; PLN-101095 and 5 more · For: Advanced or Metastatic Solid Tumor
Sites: New Haven, Connecticut; Washington D.C., District of Columbia; Atlanta, Georgia · 27 sites in all
SEED Therapeutics, Inc.Industry
NCT07197554 · 171 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 31, 2029
Drug: ST-01156 · For: Advanced Solid Tumors; Ewing Sarcoma; Hepatocellular Carcinoma (HCC) and 1 more
Sites: Duarte, California; Newport Beach, California; Boston, Massachusetts · 6 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.